Haizeng Zhang

Dr. Haizeng Zhang


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2022 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JJJing Jin
Jing Jin
YTYuan Tang
Yuan Tang
CHChen Hu
Chen Hu
LJLi-Ming Jiang
Li-Ming Jiang
JJJun Jiang
Jun Jiang
YLYexiong Li
Yexiong Li
PURPOSE: To ascertain if preoperative short-term radiotherapy followed by chemotherapy is not inferior to a standard schedule of long-term chemoradiotherapy in patients with locally advanced rectal cancer. MATERIALS AND METHODS: Patients with distal or middle-third, clinical primary tumor stage 3-4 and/or regional lymph node–positive rectal cancer were randomly assigned (1:1) to short-term radiotherapy (25 Gy in five fractions over 1 week) followed by four cycles of chemotherapy (total neoadjuvant therapy [TNT]) or chemoradiotherapy (50 Gy in 25 fractions over 5 weeks, concurrently with capecitabine [chemoradiotherapy; CRT]). Total mesorectal excision was undertaken 6-8 weeks after preoperative treatment, with two additional cycles of CAPOX (intravenous oxaliplatin [130 mg/m2, once a day] on day 1 and capecitabine [1,000 mg/m2, twice a day] from days 1 to 14) in the TNT group and six cycles of CAPOX in the CRT group. The primary end point was 3-year disease-free survival (DFS). RESULTS: Between August 2015 and August 2018, a total of 599 patients were randomly assigned to receive TNT (n = 302) or CRT (n = 297). At a median follow-up of 35.0 months, 3-year DFS was 64.5% and 62.3% in TNT and CRT groups, respectively (hazard ratio, 0.883; one-sided 95% CI, not applicable to 1.11; P < .001 for noninferiority). There was no significant difference in metastasis-free survival or locoregional recurrence, but the TNT group had better 3-year overall survival than the CRT group (86.5% v 75.1%; P = .033). Treatment effects on DFS and overall survival were similar regardless of prognostic factors. The prevalence of acute grade III-V toxicities during preoperative treatment was 26.5% in the TNT group versus 12.6% in the CRT group ( P < .001). CONCLUSION: Short-term radiotherapy with preoperative chemotherapy followed by surgery was efficacious with acceptable toxicity and could be used as an alternative to CRT for locally advanced rectal cancer.

4 June 2013 in Microbial Ecology
Verified
Journal Article
Closed access
PDF file
NWNa Wu
Na Wu
XYXi Yang
Xi Yang
RZRuifen Zhang
Ruifen Zhang
JLJun Li
Jun Li
XXXue Xiao
Xue Xiao
BZBaoli Zhu
Baoli Zhu

5 January 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
SSShuang Shang
Shuang Shang
YYYu-Wei Yang
Yu-Wei Yang
FCFei Chen
Fei Chen
LYLiang Yu
Liang Yu
SSShuo-Hao Shen
Shuo-Hao Shen
FHFang Hua
Fang Hua
TRIB3 promotes exclusion of CD8 + T cells and enhances immune evasion by inhibiting the STAT1-CXCL10 signaling axis in colorectal cancer.

24 April 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
CZChong Zhang
Chong Zhang
LZLin Zhang
Lin Zhang
TXTianlei Xu
Tianlei Xu
RXRuidong Xue
Ruidong Xue
LYLiang Yu
Liang Yu
HZHaizeng Zhang
Haizeng Zhang
Lymphatic metastases are closely associated with tumor relapse and reduced survival in colorectal cancer (CRC). How tumor cells disseminate within the lymphatic network remains largely unknown. Here, we analyze the subclonal structure of 94 tumor samples, covering the primary tumors, lymph node metastases (LNMs), and liver metastases from 10 CRC patients. We portray a high-resolution lymphatic metastatic map for CRC by dividing LNMs into paracolic, intermediate, and central subgroups. Among the 61 metastatic routes identified, 38 (62.3%) are initiated from the primary tumors, 22 (36.1%) from LNMs, and 1 from liver metastasis (1.6%). In 5 patients, we find 6 LNMs that reseed 2 or more LNMs. We summarize 3 diverse modes of metastasis in CRC and show that skip spreading of tumor cells within the lymphatic network is common. Our study sheds light on the complicated metastatic pattern in CRC and has great clinical implications.

29 January 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
YLYuying Liu
Yuying Liu
JLJiadi Lv
Jiadi Lv
JLJinyan Liu
Jinyan Liu
XLXiaoyu Liang
Xiaoyu Liang
XJXun Jin
Xun Jin
BHBo Huang
Bo Huang
Dynamic interaction with the immune system profoundly regulates tumor cell dormancy. However, it is unclear how immunological cues trigger cancer cell–intrinsic signaling pathways for entering into dormancy. Here, we show that IFN-β treatment induced tumor-repopulating cells (TRC) to enter dormancy through an indolamine 2,3-dioxygenase/kynurenine/aryl hydrocarbon receptor/p27–dependent (IDO/Kyn/AhR/p27-dependent) pathway. Strategies to block this metabolic circuitry did not relieve dormancy, but led to apoptosis of dormant TRCs in murine and human melanoma models. Specifically, blocking AhR redirected IFN-β signaling to STAT3 phosphorylation through both tyrosine and serine sites, which subsequently facilitated STAT3 nuclear translocation and subsequent binding to the p53 promoter in the nucleus. Upregulation of p53 in turn disrupted the pentose phosphate pathway, leading to excessive ROS production and dormant TRC death. Additionally, in melanoma patients, high expression of IFN-β correlated with tumor cell dormancy. Identification of this mechanism for controlling TRC dormancy by IFN-β provides deeper insights into cancer-immune interaction and potential new cancer immunotherapeutic modalities.

23 November 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SSShuang Shang
Shuang Shang
CYChen Yang
Chen Yang
FCFei Chen
Fei Chen
RXRen-Shen Xiang
Ren-Shen Xiang
HZHuan Zhang
Huan Zhang
FHFang Hua
Fang Hua
Elimination of cancer stem cells (CSCs) and reinvigoration of antitumor immunity remain unmet challenges for cancer therapy. Tumor-associated macrophages (TAMs) constitute the prominant population of immune cells in tumor tissues, contributing to the formation of CSC niches and a suppressive immune microenvironment. Here, we report that high expression of inhibitor of differentiation 1 (ID1) in TAMs correlates with poor outcome in patients with colorectal cancer (CRC). ID1 expressing macrophages maintain cancer stemness and impede CD8 + T cell infiltration. Mechanistically, ID1 interacts with STAT1 to induce its cytoplasmic distribution and inhibits STAT1-mediated SerpinB2 and CCL4 transcription, two secretory factors responsible for cancer stemness inhibition and CD8 + T cell recruitment. Reducing ID1 expression ameliorates CRC progression and enhances tumor sensitivity to immunotherapy and chemotherapy. Collectively, our study highlights the pivotal role of ID1 in controlling the protumor phenotype of TAMs and paves the way for therapeutic targeting of ID1 in CRC.